Monographie - Tigecycline - Stabilis 4.0

zadnja posodobitev :
19/11/2024

Antibiotik

Tigecycline

Brizgalka

Stabilnost raztopine

Stabilnost mešanice

Faktorji, ki vplivajo na stabilnost

Kompatibilnost

način aplikacije

Viri

pdf

Kemična formula

Lastniško ime

Lastniško ime

Sestava pomožnih snovi je med paralelami lahko različna

Eticina	Mehika
Grexyl	Mehika
Linicetil	Mehika
Mrsacin	Turčija
Tecygen	Čile
Tigecid	Turčija
Tigecilina	Argentina, Čile, Ekvador
Tigecycline	Kanada
Tigetop	Čile
Tizoxim	Argentina
Tygacil	Argentina, Avstrija, Belgija, Čile, Danska, Ekvador, Finska, Francija, Grčija, Irska, Islandija, Italija, Japonska, Kanada, Kolumbija, Luksemburg, Madžarska, Malezija, Mehika, Nemčija, Nizozemska, Norveška, nova Zelandija, Peru, Poljska, Portugalska, Romunija, Savdska Arabija, Španija, Švedska, Švica, Turčija, Velika Britanija, Venezuela, Združene države Amerike, Združeni arabski emirati
Zomiprerin	Peru

Viri

Brizgalka

Viri : Tigecycline

	Tip	objava
2262	časopis	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3128	Traduction Laboratorij	Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit Prostrakan 2013
3254	časopis	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3332	Traduction Laboratorij	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3531	Traduction Laboratorij	Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics Wockhardt 2014
3644	Traduction Laboratorij	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3674	Traduction Laboratorij	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3827	poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3887	časopis	Robiyanto R, Zaidi S.T.R, . Shastri M.D, Castelino R.L, Wanandy S.T, Jose M.D, . Patel R.P. Stability of Tigecycline in Different Types of Peritoneal Dialysis Solutions. Perit Dial Int 2016 ; 36:410-414.
4055	časopis	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	časopis	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4528	časopis	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4801	časopis	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

Mentions Légales